Back to Search
Start Over
Are There Differences in Toxicity and Efficacy between Various Bacillus Calmette-Guerin Strains in Bladder Cancer Patients? Analysis of 844 Patients
- Source :
- Urologia Internationalis. 101:277-284
- Publication Year :
- 2018
- Publisher :
- S. Karger AG, 2018.
-
Abstract
- Purpose: To evaluate if there are differences in toxicity and efficacy between different Bacillus Calmette-Guerin (BCG) stains used for intravesical immunotherapy in patients with non-muscle invasive bladder cancer. Methods: We retrospectively analysed a group of 844 patients who received TICE, RIVM and Moreau BCG strains. The allocation of the strain to each patient was random, stemming from differences in supply and distribution. The patients were analysed in terms of toxicity, recurrence-free (RFS), progression-free (PFS), cancer-specific (CSS) and overall survival (OS). Results: In the survival analysis, statistical significance was not reached in any tumour group for any clinical event. TICE caused more local and mild adverse effects and severe complications were mainly associated with RIVM strain. In a group in which the strain was changed during the course of the therapy, significantly more severe complications were observed and, in most of these cases, complications appeared right after the strain change. Conclusions: There were no differences in terms of RFS, PFS, CSS and OS after use of TICE, RIVM and Moreau strains. The complication profile differed statistically between used strains with TICE causing mostly mild complications. Also, strain change during the therapy course was associated with the increased risk of moderate to severe toxicity occurrence.
- Subjects :
- Adult
Male
medicine.medical_specialty
Urology
030232 urology & nephrology
Gastroenterology
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Species Specificity
Statistical significance
Internal medicine
medicine
Humans
In patient
Adverse effect
Survival analysis
Aged
Retrospective Studies
Aged, 80 and over
Bladder cancer
business.industry
Clinical events
Middle Aged
medicine.disease
Administration, Intravesical
Treatment Outcome
Urinary Bladder Neoplasms
030220 oncology & carcinogenesis
Toxicity
BCG Vaccine
Disease Progression
Female
Immunotherapy
Neoplasm Recurrence, Local
business
Complication
Subjects
Details
- ISSN :
- 14230399 and 00421138
- Volume :
- 101
- Database :
- OpenAIRE
- Journal :
- Urologia Internationalis
- Accession number :
- edsair.doi.dedup.....6031b2d53189f262a0b64ed9a56d1f7a